Monitor the company's progress in regaining compliance with NYSE listing standards, particularly equity-raising activities and financial performance, as failure by August 2027 could trigger delisting and severely impact liquidity and institutional ownership.
Price Chart
Executive Summary
VolitionRx received NYSE American's acceptance of its plan to regain compliance with continued listing standards, granting it until August 6, 2027 to address stockholders' equity deficiencies. The company remains under review and risks delisting if it fails to meet the plan's goals.
Key Facts
- Company received notice of non-compliance with NYSE American listing standards due to insufficient stockholders' equity under Sections 1003(a)(i), (ii), and (iii)
- NYSE American accepted the company's plan of compliance on April 22, 2026, granting an extension until August 6, 2027 to regain compliance
- The company must demonstrate sufficient progress during the plan period or face potential delisting proceedings
- Stockholders' equity requirements not met: $2M for 2 of 3 years, $4M for 3 of 4 years, or $6M for 5 of 5 years with net losses
- Company was not eligible for exemptions, including the $50M market capitalization exemption
Financial Impact
Company must increase stockholders' equity to at least $2 million, $4 million, or $6 million depending on loss history to maintain listing
Risk Factors
- Potential delisting if compliance is not achieved by August 6, 2027
- Inability to raise sufficient capital to meet equity requirements
- Continued operating losses exacerbating financial condition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001477932-26-002472 |
| Document: vnrx_ex991.htm | 0001477932-26-002472 |
| Document: 0001477932-26-002472-index-headers.html | 0001477932-26-002472 |
| Document: 0001477932-26-002472-index.html | 0001477932-26-002472 |
| Document: 0001477932-26-002472.txt | 0001477932-26-002472 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $0.2529 | awaiting T+60 | — | $0.1841 (+27.20%) |
Sep 16, 2026 5w ago | SC 13D/A | $0.2849 | awaiting T+60 | — | $0.1841 (−35.38%) |
Sep 15, 2026 5w ago | 8-K | $0.2749 | awaiting T+60 | — | $0.1841 (+33.03%) |
Sep 11, 2026 6w ago | EFFECT | $0.3102 | awaiting T+60 | — | $0.1841 (+40.65%) |
Sep 8, 2026 6w ago | S-3/A | $0.3400 | awaiting T+60 | — | $0.1841 (+45.85%) |
Sep 1, 2026 7w ago | 8-K | $0.3800 | awaiting T+60 | — | $0.1841 (+51.55%) |
Aug 24, 2026 9w ago | 8-K | $0.3846 | awaiting T+60 | — | $0.1841 (+52.13%) |
Aug 7, 2026 11w ago | 8-K | $0.7700 | awaiting T+60 | — | $0.1841 (+76.09%) |
Jul 20, 2026 14w ago | EFFECT | $1.13 $0.1847 | ▲ +83.65% | ▲ +88.50% | $0.1841 (+83.71%) |
Jun 18, 2026 18w ago | 8-K | $1.34 | awaiting T+60 | — | $0.1841 (+86.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers